Rolf Kiessling

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: ONCOIMMUNOLOGY. 2022;11(1):2093426

Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality.

Schoutrop E; Renken S; Micallef Nilsson I; Hahn P; Poiret T; Kiessling R; Wickström SL; Mattsson J; Magalhaes I
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2022;10(6):e004458

Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress.

Renken S; Nakajima T; Magalhaes I; Mattsson J; Lundqvist A; Arnér ESJ; Kiessling R; Wickström SL
Article: FRONTIERS IN ONCOLOGY. 2022;12:866763

Generation of Tumor-Specific Cytotoxic T Cells From Blood via In Vitro Expansion Using Autologous Dendritic Cells Pulsed With Neoantigen-Coupled Microbeads.

Kiessling A; Ramanathan K; Nilsson OB; Notari L; Renken S; Kiessling R; Grönlund H; Wickström SL
Article: ADVANCED SCIENCE. 2021;8(21):e2101029

Interleukin-33 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophage-Mediated Shedding Mechanism.

Wu J; Chen Z; Wickström SL; Gao J; He X; Jing X; Wu J; Du Q; Yang M; Chen Y; Zhang D; Yin X; Guo Z; Jensen L; Yang Y; Tao W; Lundqvist A; Kiessling R; Cao Y
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2021;9(5):e002171

Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood.

Rad Pour S; Pico de Coaña Y; Demorentin XM; Melief J; Thimma M; Wolodarski M; Gomez-Cabrero D; Hansson J; Kiessling R; Tegner J
Article: ONCOIMMUNOLOGY. 2021;10(1):1935557

Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients.

Van Wigcheren GF; De Haas N; Mulder TA; Horrevorts SK; Bloemendal M; Hins-Debree S; Mao Y; Kiessling R; van Herpen CML; Flórez-Grau G; Hato SV; De Vries IJM
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2020;117(50):32005-32016

Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells.

Eisinger S; Sarhan D; Boura VF; Ibarlucea-Benitez I; Tyystjärvi S; Oliynyk G; Arsenian-Henriksson M; Lane D; Wikström SL; Kiessling R; Virgilio T; Gonzalez SF; Kaczynska D; Kanatani S; Daskalaki E; Wheelock CE; Sedimbi S; Chambers BJ; Ravetch JV; Karlsson MCI
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2020;117(37):22910-22919

Visualization of human T lymphocyte-mediated eradication of cancer cells in vivo.

He X; Yin X; Wu J; Wickström SL; Duo Y; Du Q; Qin S; Yao S; Jing X; Hosaka K; Wu J; Jensen LD; Lundqvist A; Salter AI; Bräutigam L; Tao W; Chen Y; Kiessling R; Cao Y
Article: ONCOIMMUNOLOGY. 2020;9(1):1786888

PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates.

Pico de Coaña Y; Wolodarski M; van der Haar Àvila I; Nakajima T; Rentouli S; Lundqvist A; Masucci G; Hansson J; Kiessling R
Article: CANCERS. 2020;12(9):E2349-2349

Caveolin-1-Mediated Tumor Suppression Is Linked to Reduced HIF1α S-Nitrosylation and Transcriptional Activity in Hypoxia.

Sanhueza C; Bennett JC; Valenzuela-Valderrama M; Contreras P; Lobos-González L; Campos A; Wehinger S; Lladser Á; Kiessling R; Leyton L; Quest AFG
Article: CLINICAL CANCER RESEARCH. 2020;26(16):4289-4301

The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones.

Poschke IC; Hassel JC; Rodriguez-Ehrenfried A; Lindner KAM; Heras-Murillo I; Appel LM; Lehmann J; Lövgren T; Wickström SL; Lauenstein C; Roth J; König A-K; Haanen JBAG; van den Berg J; Kiessling R; Bergmann F; Flossdorf M; Strobel O; Offringa R
Article: ONCOIMMUNOLOGY. 2020;9(1):1792058

Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination.

Lövgren T; Wolodarski M; Wickström S; Edbäck U; Wallin M; Martell E; Markland K; Blomberg P; Nyström M; Lundqvist A; Jacobsson H; Ullenhag G; Ljungman P; Hansson J; Masucci G; Tell R; Poschke I; Adamson L; Mattsson J; Kiessling R
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2020;69(4):513-522

High expression of ID1 in monocytes is strongly associated with phenotypic and functional MDSC markers in advanced melanoma.

Melief J; Pico de Coaña Y; Maas R; Fennemann F-L; Wolodarski M; Hansson J; Kiessling R
Article: METHODS IN MOLECULAR BIOLOGY. 2019;1913:207-215

Establishment of Melanoma Tumor Xenograft Using Single Cell Line Suspension and Co-injection of Patient-Derived T Cells in Immune-Deficient NSG Mice.

Gunnarsdóttir FB; Kiessling R; Pico de Coaña Y
Article: METHODS IN MOLECULAR BIOLOGY. 2019;1913:181-194

Evaluating Antibody-Dependent Cell-Mediated Cytotoxicity by Flow Cytometry.

van der Haar Àvila I; Marmol P; Cany J; Kiessling R; Pico de Coaña Y
Article: METHODS IN MOLECULAR BIOLOGY. 2019;1913:167-179

Evaluating Antibody-Dependent Cell-Mediated Cytotoxicity by Chromium Release Assay.

van der Haar Àvila I; Marmol P; Kiessling R; Pico de Coaña Y
Article: METHODS IN MOLECULAR BIOLOGY. 2019;1913:133-140

Assessment of Antitumor T-Cell Responses by Flow Cytometry After Coculture of Tumor Cells with Autologous Tumor-Infiltrating Lymphocytes.

Melief J; Wickström S; Kiessling R; Pico de Coaña Y
Article: FRONTIERS IN IMMUNOLOGY. 2019;10:2766

Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display.

Wickström SL; Lövgren T; Volkmar M; Reinhold B; Duke-Cohan JS; Hartmann L; Rebmann J; Mueller A; Melief J; Maas R; Ligtenberg M; Hansson J; Offringa R; Seliger B; Poschke I; Reinherz EL; Kiessling R
Article: CANCER IMMUNOLOGY RESEARCH. 2018;6(11):1417-1425

Cripto-1 Plasmid DNA Vaccination Targets Metastasis and Cancer Stem Cells in Murine Mammary Carcinoma.

Witt K; Ligtenberg MA; Conti L; Lanzardo S; Ruiu R; Wallmann T; Tufvesson-Stiller H; Chambers BJ; Rolny C; Lladser A; Lundqvist A; Cavallo F; Kiessling R
Article: MOLECULAR THERAPY. 2018;26(6):1482-1493

Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma.

Ligtenberg MA; Pico de Coaña Y; Shmushkovich T; Yoshimoto Y; Truxova I; Yang Y; Betancur-Boissel M; Eliseev AV; Wolfson AD; Kiessling R
Article: ONCOTARGET. 2017;8(57):97439-97463

Linking CREB function with altered metabolism in murine fibroblast-based model cell lines.

Steven A; Leisz S; Wickenhauser C; Schulz K; Mougiakakos D; Kiessling R; Denkert C; Seliger B
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2017;66(10):1333-1344

Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists.

Lövgren T; Sarhan D; Truxová I; Choudhary B; Maas R; Melief J; Nyström M; Edbäck U; Vermeij R; Scurti G; Nishimura M; Masucci G; Karlsson-Parra A; Lundqvist A; Adamson L; Kiessling R
Article: ONCOTARGET. 2017;8(13):21539-21553

Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.

de Coaña YP; Wolodarski M; Poschke I; Yoshimoto Y; Yang Y; Nyström M; Edbäck U; Brage SE; Lundqvist A; Masucci GV; Hansson J; Kiessling R
Article: ONCOIMMUNOLOGY. 2017;6(2):e1261242

IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients.

Tallerico R; Cristiani CM; Staaf E; Garofalo C; Sottile R; Capone M; Pico de Coaña Y; Madonna G; Palella E; Wolodarski M; Carannante V; Mallardo D; Simeone E; Grimaldi AM; Johansson S; Frumento P; Gulletta E; Anichini A; Colucci F; Ciliberto G; Kiessling R; Kärre K; Ascierto PA; Carbone E
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2017;5:52

Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.

Laurell A; Lönnemark M; Brekkan E; Magnusson A; Tolf A; Wallgren AC; Andersson B; Adamson L; Kiessling R; Karlsson-Parra A
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2016;4:62

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, December 5th 2015

Ascierto PA; Ascierto ML; Formenti S; Gnjatic S; Hammers H; Hirsh V; Kiessling R; Melero I; Nanda R; Pawelec G; Pignata S; Romero P; Speiser DE; Fox BA; Marincola FM
Article: BLOOD. 2016;128(11):1475-1489

IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.

Mao Y; van Hoef V; Zhang X; Wennerberg E; Lorent J; Witt K; Masvidal L; Liang S; Murray S; Larsson O; Kiessling R; Lundqvist A
Article: ONCOTARGET. 2016;7(32):52061-52084

Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization.

Steven A; Leisz S; Sychra K; Hiebl B; Wickenhauser C; Mougiakakos D; Kiessling R; Denkert C; Seliger B
Article: CLINICAL CANCER RESEARCH. 2016;22(15):3849-3859

Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma.

Mao Y; Eissler N; Blanc KL; Johnsen JI; Kogner P; Kiessling R
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2016;14(1):227

Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer.

Miyan M; Schmidt-Mende J; Kiessling R; Poschke I; de Boniface J
Article: ONCOIMMUNOLOGY. 2016;5(5):e1128613

Cripto-1 vaccination elicits protective immunity against metastatic melanoma.

Ligtenberg MA; Witt K; Galvez-Cancino F; Sette A; Lundqvist A; Lladser A; Kiessling R
Article: JOURNAL OF IMMUNOLOGY. 2016;196(2):759-766

Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity.

Ligtenberg MA; Mougiakakos D; Mukhopadhyay M; Witt K; Lladser A; Chmielewski M; Riet T; Abken H; Kiessling R
Article: ONCOIMMUNOLOGY. 2016;5(1):e1052213

Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis.

Andersson E; Poschke I; Villabona L; Carlson JW; Lundqvist A; Kiessling R; Seliger B; Masucci GV
Article: ONCOIMMUNOLOGY. 2016;5(12):e1232222

Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade.

Eissler N; Mao Y; Brodin D; Reuterswärd P; Andersson Svahn H; Johnsen JI; Kiessling R; Kogner P
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2015;13:374

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
Article: HUMAN GENE THERAPY. CLINICAL DEVELOPMENT. 2015;26(2):79-81

Adoptive Engineered T-Cell Trials to Achieve Cancer Killing (ATTACK).
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2015;45(6):1783-1793

Dendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-β.

Sarhan D; Palma M; Mao Y; Adamson L; Kiessling R; Mellstedt H; Österborg A; Lundqvist A
Article: ONCOIMMUNOLOGY. 2015;4(4):e998538

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L; Smyth MJ; Drake CG; Abastado J-P; Apte RN; Ayyoub M; Blay J-Y; Bonneville M; Butterfield LH; Caignard A; Castelli C; Cavallo F; Celis E; Chen L; Colombo MP; Comin-Anduix B; Coukos G; Dhodapkar MV; Dranoff G; Frazer IH; Fridman W-H; Gabrilovich DI; Gilboa E; Gnjatic S; Jäger D; Kalinski P; Kaufman HL; Kiessling R; Kirkwood J; Knuth A; Liblau R; Lotze MT; Lugli E; Marincola F; Melero I; Melief CJ; Mempel TR; Mittendorf EA; Odun K; Overwijk WW; Palucka AK; Parmiani G; Ribas A; Romero P; Schreiber RD; Schuler G; Srivastava PK; Tartour E; Valmori D; van der Burg SH; van der Bruggen P; van den Eynde BJ; Wang E; Zou W; Whiteside TL; Speiser DE; Pardoll DM; Restifo NP; Anderson AC
Article: PLOS ONE. 2015;10(6):e0129786

Methylcholanthrene-Induced Sarcomas Develop Independently from NOX2-Derived ROS.

Ligtenberg MA; Çınar Ö; Holmdahl R; Mougiakakos D; Kiessling R
Article: PLOS ONE. 2015;10(10):e0139809

Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells.

Okita R; Wolf D; Yasuda K; Maeda A; Yukawa T; Saisho S; Shimizu K; Yamaguchi Y; Oka M; Nakayama E; Lundqvist A; Kiessling R; Seliger B; Nakata M
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2014;63(10):1061-1071

A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma.

Poschke I; Lövgren T; Adamson L; Nyström M; Andersson E; Hansson J; Tell R; Masucci GV; Kiessling R
Article: MATRIX BIOLOGY. 2014;38:69-83

Laminins 411 and 421 differentially promote tumor cell migration via α6β1 integrin and MCAM (CD146).

Ishikawa T; Wondimu Z; Oikawa Y; Gentilcore G; Kiessling R; Egyhazi Brage S; Hansson J; Patarroyo M
Article: CLINICAL CANCER RESEARCH. 2014;20(15):4096-4106

Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity.

Mao Y; Sarhan D; Steven A; Seliger B; Kiessling R; Lundqvist A
Article: JOURNAL OF IMMUNOLOGY. 2013;191(12):6261-6272

The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer.

Mimura K; Shiraishi K; Mueller A; Izawa S; Kua L-F; So J; Yong W-P; Fujii H; Seliger B; Kiessling R; Kono K
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2013;11:290

Tumor-dependent increase of serum amino acid levels in breast cancer patients has diagnostic potential and correlates with molecular tumor subtypes.

Poschke I; Mao Y; Kiessling R; de Boniface J
Article: HUMAN VACCINES & IMMUNOTHERAPEUTICS. 2013;9(10):2189-2195

NF-κB activation during intradermal DNA vaccination is essential for eliciting tumor protective antigen-specific CTL responses.

Ligtenberg MA; Rojas-Colonelli N; Kiessling R; Lladser A
Article: CANCER IMMUNOLOGY RESEARCH. 2013;1(3):158-162

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production.

Pico de Coaña Y; Poschke I; Gentilcore G; Mao Y; Nyström M; Hansson J; Masucci GV; Kiessling R
Article: STEM CELLS. 2013;31(8):1715-1725

Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation.

Jitschin R; Mougiakakos D; Von Bahr L; Völkl S; Moll G; Ringden O; Kiessling R; Linder S; Le Blanc K
Article: CANCER RESEARCH. 2013;73(13):3877-3887

Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms.

Mao Y; Poschke I; Wennerberg E; Pico de Coaña Y; Egyhazi Brage S; Schultz I; Hansson J; Masucci G; Lundqvist A; Kiessling R
Article: ONCOIMMUNOLOGY. 2012;1(8):1305-1312

Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients.

de Boniface J; Mao Y; Schmidt-Mende J; Kiessling R; Poschke I
Article: ONCOIMMUNOLOGY. 2012;1(7):1104-1110

Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression.

Inoue M; Mimura K; Izawa S; Shiraishi K; Inoue A; Shiba S; Watanabe M; Maruyama T; Kawaguchi Y; Inoue S; Kawasaki T; Choudhury A; Katoh R; Fujii H; Kiessling R; Kono K
Article: INTERNATIONAL JOURNAL OF CANCER. 2012;131(7):1611-1620

Tumor-induced changes in the phenotype of blood-derived and tumor-associated T cells of early stage breast cancer patients.

Poschke I; De Boniface J; Mao Y; Kiessling R
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2012;61(8):1243-1253

Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer.

Andersson E; Villabona L; Bergfeldt K; Carlson JW; Ferrone S; Kiessling R; Seliger B; Masucci GV
Article: JOURNAL OF MOLECULAR MEDICINE-JMM. 2012;90(8):935-944

High expression of GCLC is associated with malignant melanoma of low oxidative phenotype and predicts a better prognosis.

Mougiakakos D; Okita R; Ando T; Dürr C; Gadiot J; Ichikawa J; Zeiser R; Blank C; Johansson CC; Kiessling R
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2012;287(29):24320-24329

HER-2/neu-mediated down-regulation of biglycan associated with altered growth properties.

Recktenwald CV; Leisz S; Steven A; Mimura K; Müller A; Wulfänger J; Kiessling R; Seliger B
Article: INTERNATIONAL JOURNAL OF CANCER. 2012;131(1):129-139

Tumor-dependent down-regulation of the ζ-chain in T-cells is detectable in early breast cancer and correlates with immune cell function.

Boniface JD; Poschke I; Mao Y; Kiessling R
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2012;61(6):827-838

Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines.

Poschke I; Mao Y; Adamson L; Salazar-Onfray F; Masucci G; Kiessling R
Article: INTERNATIONAL JOURNAL OF CANCER. 2012;130(5):1120-1127

Nuclear HER3 is associated with favorable overall survival in uveal melanoma.

Trocmé E; Mougiakakos D; Johansson CC; All-Eriksson C; Economou MA; Larsson O; Seregard S; Kiessling R; Lin Y
Article: JOURNAL OF IMMUNOLOGY. 2012;188(5):2136-2145

HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.

Okita R; Mougiakakos D; Ando T; Mao Y; Sarhan D; Wennerberg E; Seliger B; Lundqvist A; Mimura K; Kiessling R
Article: PLOS ONE. 2012;7(7):e41345

Comparative expression profiling of distinct T cell subsets undergoing oxidative stress.

Lichtenfels R; Mougiakakos D; Johansson CC; Dressler SP; Recktenwald CV; Kiessling R; Seliger B
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2011;9:214

Defining the critical hurdles in cancer immunotherapy.

Fox BA; Schendel DJ; Butterfield LH; Aamdal S; Allison JP; Ascierto PA; Atkins MB; Bartunkova J; Bergmann L; Berinstein N; Bonorino CC; Borden E; Bramson JL; Britten CM; Cao X; Carson WE; Chang AE; Characiejus D; Choudhury AR; Coukos G; de Gruijl T; Dillman RO; Dolstra H; Dranoff G; Durrant LG; Finke JH; Galon J; Gollob JA; Gouttefangeas C; Grizzi F; Guida M; Håkansson L; Hege K; Herberman RB; Hodi FS; Hoos A; Huber C; Hwu P; Imai K; Jaffee EM; Janetzki S; June CH; Kalinski P; Kaufman HL; Kawakami K; Kawakami Y; Keilholtz U; Khleif SN; Kiessling R; Kotlan B; Kroemer G; Lapointe R; Levitsky HI; Lotze MT; Maccalli C; Maio M; Marschner J-P; Mastrangelo MJ; Masucci G; Melero I; Melief C; Murphy WJ; Nelson B; Nicolini A; Nishimura MI; Odunsi K; Ohashi PS; O'Donnell-Tormey J; Old LJ; Ottensmeier C; Papamichail M; Parmiani G; Pawelec G; Proietti E; Qin S; Rees R; Ribas A; Ridolfi R; Ritter G; Rivoltini L; Romero PJ; Salem ML; Scheper RJ; Seliger B; Sharma P; Shiku H; Singh-Jasuja H; Song W; Straten PT; Tahara H; Tian Z; van Der Burg SH; von Hoegen P; Wang E; Welters MJ; Winter H; Withington T; Wolchok JD; Xiao W; Zitvogel L; Zwierzina H; Marincola FM; Gajewski TF; Wigginton JM; Disis ML
Article: INTERNATIONAL JOURNAL OF CANCER. 2011;129(10):2408-2416

Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.

Mimura K; Kono K; Maruyama T; Watanabe M; Izawa S; Shiba S; Mizukami Y; Kawaguchi Y; Inoue M; Kono T; Choudhury A; Kiessling R; Fujii H
Article: IMMUNOBIOLOGY. 2011;216(10):1117-1126

A synthetic peptide homologous to IL-10 functional domain induces monocyte differentiation to TGF-β+ tolerogenic dendritic cells.

López MN; Pesce B; Kurte M; Pérez C; Segal G; Roa J; Aguillón JC; Mendoza-Naranjo A; Gesser B; Larsen C; Villablanca A; Choudhury A; Kiessling R; Salazar-Onfray F
Article: BLOOD. 2011;117(18):4826-4835

The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells.

Mougiakakos D; Jitschin R; Johansson CC; Okita R; Kiessling R; Le Blanc K
Article: JOURNAL OF IMMUNOTHERAPY. 2011;34(4):336-342

Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity?

Sundin M; D'arcy P; Johansson CC; Barrett AJ; Lönnies H; Sundberg B; Nava S; Kiessling R; Mougiakakos D; Le Blanc K
Article: MOLECULAR THERAPY. 2011;19(3):594-601

DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity.

Lladser A; Mougiakakos D; Tufvesson H; Ligtenberg MA; Quest AF; Kiessling R; Ljungberg K
Article: BLOOD. 2011;117(3):857-861

Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress.

Mougiakakos D; Johansson CC; Jitschin R; Böttcher M; Kiessling R
Article: INTERNATIONAL JOURNAL OF CANCER. 2011;128(2):390-401

T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2.

Mimura K; Ando T; Poschke I; Mougiakakos D; Johansson CC; Ichikawa J; Okita R; Nishimura MI; Handke D; Krug N; Choudhury A; Seliger B; Kiessling R
Article: CANCER RESEARCH. 2010;70(19):7431-7441

Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors.

Triulzi C; Vertuani S; Curcio C; Antognoli A; Seibt J; Akusjärvi G; Wei W-Z; Cavallo F; Kiessling R
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2010;8:53

Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.

Norell H; Poschke I; Charo J; Wei WZ; Erskine C; Piechocki MP; Knutson KL; Bergh J; Lidbrink E; Kiessling R
Article: CANCER RESEARCH. 2010;70(11):4335-4345

Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.

Poschke I; Mougiakakos D; Hansson J; Masucci GV; Kiessling R
Article: INTERNATIONAL JOURNAL OF CANCER. 2010;126(11):2682-2689

Expression and prognostic significance of iNOS in uveal melanoma.

Johansson CC; Mougiakakos D; Trocme E; All-Ericsson C; Economou MA; Larsson O; Seregard S; Kiessling R
Article: CANCER. 2010;116(9):2224-2233

Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma.

Mougiakakos D; Johansson CC; Trocme E; All-Ericsson C; Economou MA; Larsson O; Seregard S; Kiessling R
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2010;59(1):81-92

Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma.

Lladser A; Ljungberg K; Tufvesson H; Tazzari M; Roos A-K; Quest AFG; Kiessling R
Article: JOURNAL OF IMMUNOLOGY. 2009;183(8):4921-4930

Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells.

Carlsten M; Norell H; Bryceson YT; Poschke I; Schedvins K; Ljunggren H-G; Kiessling R; Malmberg K-J
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2009;58(10):1599-1608

The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma.

Helgadottir H; Andersson E; Villabona L; Kanter L; van der Zanden H; Haasnoot GW; Seliger B; Bergfeldt K; Hansson J; Ragnarsson-Olding B; Kiessling R; Masucci GV
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2009;58(7):1085-1094

Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma.

Johansson CC; Egyházi S; Masucci G; Harlin H; Mougiakakos D; Poschke I; Nilsson B; Garberg L; Tuominen R; Linden D; Stolt MF; Hansson J; Kiessling R
Article: EUROPEAN JOURNAL OF CANCER. 2009;45(8):1424-1431

Improving the efficacy of cancer immunotherapy.

Copier J; Dalgleish AG; Britten CM; Finke LH; Gaudernack G; Gnjatic S; Kallen K; Kiessling R; Schuessler-Lenz M; Singh H; Talmadge J; Zwierzina H; Håkansson L
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2009;58(5):653-664

HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice.

Vertuani S; Triulzi C; Roos AK; Charo J; Norell H; Lemonnier F; Pisa P; Seliger B; Kiessling R
Article: BLOOD. 2009;113(15):3542-3545

Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death.

Mougiakakos D; Johansson CC; Kiessling R
Article: JOURNAL OF IMMUNOLOGY. 2008;181(12):8382-8390

Transduction with the antioxidant enzyme catalase protects human T cells against oxidative stress.

Ando T; Mimura K; Johansson CC; Hanson MG; Mougiakakos D; Larsson C; Martins da Palma T; Sakurai D; Norell H; Li M; Nishimura MI; Kiessling R
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2008;105(45):17481-17486

Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas.

Kruschinski A; Moosmann A; Poschke I; Norell H; Chmielewski M; Seliger B; Kiessling R; Blankenstein T; Abken H; Charo J
Article: LAKARTIDNINGEN. 2008;105(36):2402-2404

[Therapeutic vaccines against cancer and infectious diseases. Great possibilities in the research--small clinical progress so far].

Kiessling R; Ljungberg K; Von Gabain A
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2008;99(1):57-64

Analysis of gamma delta V region usage in normal and diseased human intestinal biopsies and peripheral blood by polymerase chain reaction (PCR) and flow cytometry.

Bucht A; Söderström K; Esin S; Grunewald J; Hagelberg S; Magnusson I; Wigzell H; Grönberg A; Kiessling R
Article: JOURNAL OF IMMUNOLOGY. 2008;180(6):3766-3774

Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes.

Hallermalm K; Seki K; De Geer A; Motyka B; Bleackley RC; Jager MJ; Froelich CJ; Kiessling R; Levitsky V; Levitskaya J
Article: JOURNAL OF IMMUNOLOGY. 2007;179(7):4513-4519

The CD16- CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56(dim) subset.

Harlin H; Hanson M; Johansson CC; Sakurai D; Poschke I; Norell H; Malmberg K-J; Kiessling R
Article: HLA. 2007;70(3):205-213

Analysis of HLA class I-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer.

Gamzatova Z; Villabona L; van der Zanden H; Haasnoot GW; Andersson E; Kiessling R; Seliger B; Kanter L; Dalianis T; Bergfeldt K; Masucci GV
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2007;37(8):2196-2204

IFN-gamma regulates Fas ligand expression in human CD4+ T lymphocytes and controls their anti-mycobacterial cytotoxic functions.

Boselli D; Losana G; Bernabei P; Bosisio D; Drysdale P; Kiessling R; Gaston JSH; Lammas D; Casanova J-L; Kumararatne DS; Novelli F
Article: JOURNAL OF IMMUNOLOGY. 2007;178(11):6949-6957

Functional gap junctions facilitate melanoma antigen transfer and cross-presentation between human dendritic cells.

Mendoza-Naranjo A; Saéz PJ; Johansson CC; Ramírez M; Mandakovic D; Pereda C; López MN; Kiessling R; Sáez JC; Salazar-Onfray F
Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2007;48(3):1219-1227

Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy.

López MN; Pereda C; Ramírez M; Mendoza-Naranjo A; Serrano A; Ferreira A; Poblete R; Kalergis AM; Kiessling R; Salazar-Onfray F
Article: CANCER RESEARCH. 2007;67(3):1317-1325

DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells.

Carlsten M; Björkström NK; Norell H; Bryceson Y; van Hall T; Baumann BC; Hanson M; Schedvins K; Kiessling R; Ljunggren H-G; Malmberg K-J
Article: JOURNAL OF IMMUNOLOGY. 2006;177(11):7540-7550

Cytotoxic T lymphocytes induce caspase-dependent and -independent cell death in neuroblastomas in a MHC-nonrestricted fashion.

De Geer A; Kiessling R; Levitsky V; Levitskaya J
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2006;56(2):193-204

Retinoic acid elicits cytostatic, cytotoxic and immunomodulatory effects on uveal melanoma cells.

Vertuani S; Dubrovska E; Levitsky V; Jager MJ; Kiessling R; Levitskaya J
Article: CANCER RESEARCH. 2006;66(12):6387-6394

Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity.

Norell H; Carlsten M; Ohlum T; Malmberg K-J; Masucci G; Schedvins K; Altermann W; Handke D; Atkins D; Seliger B; Kiessling R
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2006;103(24):9208-9213

A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth.

Holmgren L; Ambrosino E; Birot O; Tullus C; Veitonmäki N; Levchenko T; Carlson L-M; Musiani P; Iezzi M; Curcio C; Forni G; Cavallo F; Kiessling R
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2006;55(6):653-662

Interferon-gamma renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells.

Kaplan BLF; Norell H; Callender GG; Ohlum T; Kiessling R; Nishimura MI
Article: JOURNAL OF IMMUNOTHERAPY. 2005;28(4):389-395

Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer.

Miller AM; Ozenci V; Kiessling R; Pisa P
Article: CANCER RESEARCH. 2005;65(13):5953-5957

A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors.

Tegerstedt K; Lindencrona JA; Curcio C; Andreasson K; Tullus C; Forni G; Dalianis T; Kiessling R; Ramqvist T
Article: JOURNAL OF IMMUNOLOGY. 2005;174(10):6080-6087

Preferential cell death of CD8+ effector memory (CCR7-CD45RA-) T cells by hydrogen peroxide-induced oxidative stress.

Takahashi A; Hanson MGV; Norell HR; Havelka AM; Kono K; Malmberg K-J; Kiessling RVR
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2004;53(12):1085-1092

Comparison of PSA-specific CD8+ CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins.

Pavlenko M; Roos A-K; Leder C; Hansson L-O; Kiessling R; Levitskaya E; Pisa P
Article: JOURNAL OF VIROLOGY. 2004;78(20):11321-11326

Protective efficacy of a DNA influenza virus vaccine is markedly increased by the coadministration of a Schiff base-forming drug.

Charo J; Lindencrona JA; Carlson L-M; Hinkula J; Kiessling R
Article: CANCER RESEARCH. 2004;64(18):6775-6782

Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes.

Hallermalm K; De Geer A; Kiessling R; Levitsky V; Levitskaya J
Article: BRITISH JOURNAL OF CANCER. 2004;91(4):688-694

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

Pavlenko M; Roos A-K; Lundqvist A; Palmborg A; Miller AM; Ozenci V; Bergman B; Egevad L; Hellström M; Kiessling R; Masucci G; Wersäll P; Nilsson S; Pisa P
Article: JOURNAL OF IMMUNOLOGY. 2004;173(3):1731-1737

A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and Transporter associated with Antigen Processing 1/2 in human melanoma cells.

Kurte M; López M; Aguirre A; Escobar A; Aguillón JC; Charo J; Larsen CG; Kiessling R; Salazar-Onfray F
Article: INTERNATIONAL JOURNAL OF CANCER. 2004;109(2):259-264

CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells.

Lindencrona JA; Preiss S; Kammertoens T; Schüler T; Piechocki M; Wei W-Z; Seliger B; Blankenstein T; Kiessling R
Article: JOURNAL OF IMMUNOLOGY. 2004;172(6):3501-3508

Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues.

Vertuani S; Sette A; Sidney J; Southwood S; Fikes J; Keogh E; Lindencrona JA; Ishioka G; Levitskaya J; Kiessling R
Article: INTERNATIONAL JOURNAL OF CANCER. 2004;108(1):71-77

Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines.

Choudhury A; Charo J; Parapuram SK; Hunt RC; Hunt DM; Seliger B; Kiessling R
Article: CYTOTHERAPY. 2004;6(4):363-371

Development of a technology platform for large-scale clinical grade production of DC.

Adamson L; Palmborg A; Svensson A; Lundqvist A; Hansson M; Kiessling R; Masucci G; Mellstedt H; Pisa P
Article: CANCER RESEARCH. 2003;63(22):8006-8013

Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes.

Vertuani S; De Geer A; Levitsky V; Kogner P; Kiessling R; Levitskaya J
Article: INTERNATIONAL IMMUNOLOGY. 2003;15(6):751-763

Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells.

Ramakrishna V; Ross MM; Petersson M; Gatlin CC; Lyons CE; Miller CL; Myers HE; McDaniel M; Karns LR; Kiessling R; Parmiani G; Flyer DC
Article: INFECTION AND IMMUNITY. 2002;70(12):6652-6657

Marked enhancement of the antigen-specific immune response by combining plasmid DNA-based immunization with a Schiff base-forming drug.

Charo J; Sundbäck M; Wasserman K; Ciupitu A-MT; Mirzai B; van der Zee R; Kiessling R
Article: JOURNAL OF CLINICAL INVESTIGATION. 2002;110(10):1515-1523

IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism.

Malmberg K-J; Levitsky V; Norell H; de Matos CT; Carlsten M; Schedvins K; Rabbani H; Moretta A; Söderström K; Levitskaya J; Kiessling R
Article: CLINICAL CANCER RESEARCH. 2002;8(11):3394-3400

Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer.

Kono K; Takahashi A; Sugai H; Fujii H; Choudhury AR; Kiessling R; Matsumoto Y
Article: JOURNAL OF HYPERTENSION. 2002;20(9):1815-1820

Circulating heat shock protein and heat shock protein antibody levels in established hypertension.

Pockley AG; De Faire U; Kiessling R; Lemne C; Thulin T; Frostegård J
Article: BRITISH JOURNAL OF CANCER. 2002;87(4):414-422

Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker.

Salazar-Onfray F; López M; Lundqvist A; Aguirre A; Escobar A; Serrano A; Korenblit C; Petersson M; Chhajlani V; Larsson O; Kiessling R
Article: HUMAN IMMUNOLOGY. 2002;63(6):444-451

HLA expression in uveal melanoma: there is no rule without some exception.

Jager MJ; Hurks HMH; Levitskaya J; Kiessling R
Article: CLINICAL CANCER RESEARCH. 2002;8(6):1772-1778

A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer.

Malmberg K-J; Lenkei R; Petersson M; Ohlum T; Ichihara F; Glimelius B; Frödin J-E; Masucci G; Kiessling R
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2002;51(3):163-170

Immunization with heat shock protein 70 from methylcholanthrene-induced sarcomas induces tumor protection correlating with in vitro T cell responses.

Ciupitu A-MT; Petersson M; Kono K; Charo J; Kiessling R
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2002;51(3):139-144

Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X(L).

Lundqvist A; Nagata T; Kiessling R; Pisa P
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2002;55(1):2-13

Hyaluronic acid and chondroitin sulphate A rapidly promote differentiation of immature DC with upregulation of costimulatory and antigen-presenting molecules, and enhancement of NF-kappaB and protein kinase activity.

Yang R; Yan Z; Chen F; Hansson GK; Kiessling R
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2001;31(12):3602-3611

The identification of a common pathogen-specific HLA class I A*0201-restricted cytotoxic T cell epitope encoded within the heat shock protein 65.

Charo J; Geluk A; Sundbäck M; Mirzai B; Diehl AD; Malmberg KJ; Achour A; Huriguchi S; van Meijgaarden KE; Drijfhout JW; Beekman N; van Veelen P; Ossendorp F; Ottenhoff TH; Kiessling R
Article: HUMAN GENE THERAPY. 2001;12(14):1797-1804

DNA immunization of HLA transgenic mice with a plasmid expressing mycobacterial heat shock protein 65 results in HLA class I- and II-restricted T cell responses that can be augmented by cytokines.

Charo J; Sundbäck M; Geluk A; Ottenhoff T; Kiessling R
Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2001;42(10):2153-2156

Association of HLA class I and class II antigen expression and mortality in uveal melanoma.

Ericsson C; Seregard S; Bartolazzi A; Levitskaya E; Ferrone S; Kiessling R; Larsson O
Article: JOURNAL OF IMMUNOLOGY. 2001;167(5):2595-2601

Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappaB activation.

Malmberg KJ; Arulampalam V; Ichihara F; Petersson M; Seki K; Andersson T; Lenkei R; Masucci G; Pettersson S; Kiessling R
Article: BLOOD. 2001;98(4):1108-1115

Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface.

Hallermalm K; Seki K; Wei C; Castelli C; Rivoltini L; Kiessling R; Levitskaya J
Article: JOURNAL OF CELL SCIENCE. 2001;114(Pt 2):423-433

Laminin-8 (alpha4beta1gamma1) is synthesized by lymphoid cells, promotes lymphocyte migration and costimulates T cell proliferation.

Geberhiwot T; Assefa D; Kortesmaa J; Ingerpuu S; Pedraza C; Wondimu Z; Charo J; Kiessling R; Virtanen I; Tryggvason K; Patarroyo M
Article: CANCER RESEARCH. 2001;61(1):222-227

Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells.

Castelli C; Ciupitu AM; Rini F; Rivoltini L; Mazzocchi A; Kiessling R; Parmiani G
Article: BLOOD. 2000;96(9):3086-3093

The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations.

Agerberth B; Charo J; Werr J; Olsson B; Idali F; Lindbom L; Kiessling R; Jörnvall H; Wigzell H; Gudmundsson GH
Article: HYPERTENSION. 2000;36(2):303-307

Circulating heat shock protein 60 is associated with early cardiovascular disease.

Pockley AG; Wu R; Lemne C; Kiessling R; de Faire U; Frostegård J
Article: INTERNATIONAL JOURNAL OF CANCER. 2000;87(3):349-359

HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.

Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Article: JOURNAL OF IMMUNOLOGY. 2000;165(1):25-33

T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity.

Sandberg JK; Franksson L; Sundbäck J; Michaelsson J; Petersson M; Achour A; Wallin RP; Sherman NE; Bergman T; Jörnvall H; Hunt DF; Kiessling R; Kärre K
Article: JOURNAL OF IMMUNOLOGY. 1999;163(11):5913-5919

A long-term memory obtained by genetic immunization results in full protection from a mammary adenocarcinoma expressing an EBV gene.

Charo J; Ciupitu AM; Le Chevalier De Préville A; Trivedi P; Klein G; Hinkula J; Kiessling R
Article: JOURNAL OF IMMUNOLOGY. 1999;163(8):4207-4212

NK cell triggering by the human costimulatory molecules CD80 and CD86.

Wilson JL; Charo J; Martín-Fontecha A; Dellabona P; Casorati G; Chambers BJ; Kiessling R; Bejarano MT; Ljunggren HG
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 1999;48(7):353-362

Tumor-induced immune dysfunction.

Kiessling R; Wasserman K; Horiguchi S; Kono K; Sjöberg J; Pisa P; Petersson M
Article: JOURNAL OF IMMUNOLOGY. 1999;163(2):1037-1044

Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas.

Rongcun Y; Salazar-Onfray F; Charo J; Malmberg KJ; Evrin K; Maes H; Kono K; Hising C; Petersson M; Larsson O; Lan L; Appella E; Sette A; Celis E; Kiessling R
Article: CANCER RESEARCH. 1999;59(12):2950-2956

Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells.

Horiguchi S; Petersson M; Nakazawa T; Kanda M; Zea AH; Ochoa AC; Kiessling R
Article: IMMUNOLOGY LETTERS. 1999;67(3):243-249

Generation and function of bone marrow-derived dendritic cells from CD4/CD8(-/-) double-knockout mice.

Corsi MM; Sandberg JK; Wasserman K; Maes HH; Kiessling R
Article: INTERNATIONAL JOURNAL OF CANCER. 1998;78(2):202-208

Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes.

Kono K; Rongcun Y; Charo J; Ichihara F; Celis E; Sette A; Appella E; Sekikawa T; Matsumoto Y; Kiessling R
Article: MELANOMA RESEARCH. 1998;8(5):389-397

Expression of the insulin-like growth factor-1 receptor and its anti-apoptotic effect in malignant melanoma: a potential therapeutic target.

Kanter-Lewensohn L; Dricu A; Wang M; Wejde J; Kiessling R; Larsson O
Article: CYTOKINE. 1998;10(10):747-755

Interferon gamma impairs the ability of monocyte-derived dendritic cells to present tumour-specific and allo-specific antigens and reduces their expression of CD1A, CD80 AND CD4.

Rongcun Y; Maes H; Corsi M; Dellner F; Wen T; Kiessling R
Article: JOURNAL OF IMMUNOLOGY. 1998;161(5):2099-2105

Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1.

Petersson M; Charo J; Salazar-Onfray F; Noffz G; Mohaupt M; Qin Z; Klein G; Blankenstein T; Kiessling R
Article: JOURNAL OF EXPERIMENTAL MEDICINE. 1998;187(5):685-691

Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes.

Ciupitu AM; Petersson M; O'Donnell CL; Williams K; Jindal S; Kiessling R; Welsh RM
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1998;47(3):254-262

Decreased expression of signal-transducing CD3 zeta chains in T cells from the joints and peripheral blood of rheumatoid arthritis patients.

Matsuda M; Ulfgren AK; Lenkei R; Petersson M; Ochoa AC; Lindblad S; Andersson P; Klareskog L; Kiessling R
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1997;94(21):11496-11501

Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells.

Wolpert EZ; Petersson M; Chambers BJ; Sandberg JK; Kiessling R; Ljunggren HG; Kärre K
Article: CANCER RESEARCH. 1997;57(19):4348-4355

Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells.

Salazar-Onfray F; Nakazawa T; Chhajlani V; Petersson M; Kärre K; Masucci G; Celis E; Sette A; Southwood S; Appella E; Kiessling R
Article: JOURNAL OF IMMUNOLOGY. 1997;159(7):3195-3202

Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10.

Salazar-Onfray F; Charo J; Petersson M; Freland S; Noffz G; Qin Z; Blankenstein T; Ljunggren HG; Kiessling R
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1997;27(8):1988-1993

CD28 is not required for rejection of unmanipulated syngeneic and autologous tumors.

Wen T; Kono K; Shahinian A; Kiessling R; Mak TW; Klein G
Article: STEM CELLS AND DEVELOPMENT. 1997;6(3):253-260

Efficient harvest of in vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytapheresis).

Masucci G; Svensson A; Hansson M; Hansson J; Nakazawa T; Salazar F; Petersson M; Kiessling R
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1997;45(6):678-682

Conversion of in vitro cultured human monocytes into effective presenters of an HER2/neu-encoded CTL peptide epitope.

Wasserman K; Corsi MM; Szekel L; Kono K; Maes HH; Kiessling R
Article: INTERNATIONAL JOURNAL OF CANCER. 1997;70(1):112-119

Mechanisms of escape from CD8+ T-cell clones specific for the HER-2/neu proto-oncogene expressed in ovarian carcinomas: related and unrelated to decreased MHC class 1 expression.

Kono K; Halapi E; Hising C; Petersson M; Gerdin E; Vanky F; Kiessling R
Article: HYPERTENSION. 1997;29(1 Pt 1):40-44

Association of serum antibodies to heat-shock protein 65 with borderline hypertension.

Frostegård J; Lemne C; Andersson B; van der Zee R; Kiessling R; de Faire U
Article: CLINICAL CANCER RESEARCH. 1996;2(11):1825-1828

Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer.

Kono K; Ressing ME; Brandt RM; Melief CJ; Potkul RK; Andersson B; Petersson M; Kast WM; Kiessling R
Article: INFECTION AND IMMUNITY. 1996;64(10):4356-4358

Induction of heat shock protein 60 expression in human monocytic cell lines infected with Mycobacterium leprae.

Beimnet K; Söderström K; Jindal S; Grönberg A; Frommel D; Kiessling R
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1996;26(6):1308-1313

Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity.

Kono K; Salazar-Onfray F; Petersson M; Hansson J; Masucci G; Wasserman K; Nakazawa T; Anderson P; Kiessling R
Article: JOURNAL OF IMMUNOLOGY. 1996;156(6):2331-2339

Increased frequency of abnormal gamma delta T cells in blood of patients with inflammatory bowel diseases.

Söderström K; Bucht A; Halapi E; Grönberg A; Magnusson I; Kiessling R
Article: ATHEROSCLEROSIS. 1996;121(1):93-103

Induction of heat shock protein in monocytic cells by oxidized low density lipoprotein.

Frostegård J; Kjellman B; Gidlund M; Andersson B; Jindal S; Kiessling R
Article: SEMINARS IN IMMUNOPATHOLOGY. 1996;18(2):227-242

Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules.

Kiessling R; Kono K; Petersson M; Wasserman K
Article: CANCER RESEARCH. 1995;55(23):5648-5655

Methylcholanthrene-induced mouse sarcomas express individually distinct major histocompatibility complex class I-associated peptides recognized by specific CD8+ T-cell lines.

Kono K; Petersson M; Ciupitu AM; Wen T; Klein G; Kiessling R
Article: INTERNATIONAL JOURNAL OF CANCER. 1995;63(3):366-371

Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma.

Nakagomi H; Pisa P; Pisa EK; Yamamoto Y; Halapi E; Backlin K; Juhlin C; Kiessling R
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1995;42(1):34-38

Engagement of MHC class I proteins on natural killer cells inhibits their killing capacity.

Petersson MG; Grönberg A; Kiessling R; Ferm MT
Article: JOURNAL OF IMMUNOLOGY. 1995;154(12):6291-6298

IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression.

Salazar-Onfray F; Petersson M; Franksson L; Matsuda M; Blankenstein T; Kärre K; Kiessling R
Article: INTERNATIONAL JOURNAL OF CANCER. 1995;61(6):765-772

Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease.

Matsuda M; Petersson M; Lenkei R; Taupin JL; Magnusson I; Mellstedt H; Anderson P; Kiessling R
Visa fler

Alla övriga publikationer

Letter: ACTA ONCOLOGICA. 2022;61(7):869-873

Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial.

Backlund E; Yang M; Grozman V; Masucci G; Falkenius J; Eriksson H; Jovanovic B; Hammarlund K; Isacsson U; Radu C; Abel E; Karlsson K; Palanco Zamora R; Wersäll P; Edbäck U; Wickström S; Darai Ramqvist E; Egyhazi Brage S; Kiessling R; Viktorsson K; Franzén B; Lewensohn R; Olofsson Bagge R; Ullenhag GJ; Ny L; Lindberg K; Helgadottir H
Review: ONCOGENE. 2021;40(2):421-435

Counteracting CAR T cell dysfunction.

Poorebrahim M; Melief J; Pico de Coaña Y; L Wickström S; Cid-Arregui A; Kiessling R
Review: PHARMACOLOGY & THERAPEUTICS. 2020;214:107603

Genetically modified immune cells targeting tumor antigens.

Poorebrahim M; Abazari MF; Sadeghi S; Mahmoudi R; Kheirollahi A; Askari H; Wickström SL; Poortahmasebi V; Lundqvist A; Kiessling R; Cid-Arregui A
Editorial comment: JOURNAL OF CLINICAL INVESTIGATION. 2016;126(2):480-482

TAP-ing into TIEPPs for cancer immunotherapy.

Kiessling R
Review: TRENDS IN MOLECULAR MEDICINE. 2015;21(8):482-491

Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.

Pico de Coaña Y; Choudhury A; Kiessling R
Review: ONCOTARGET. 2014;5(24):12472-12508

Classification of current anticancer immunotherapies.

Galluzzi L; Vacchelli E; Bravo-San Pedro J-M; Buqué A; Senovilla L; Baracco EE; Bloy N; Castoldi F; Abastado J-P; Agostinis P; Apte RN; Aranda F; Ayyoub M; Beckhove P; Blay J-Y; Bracci L; Caignard A; Castelli C; Cavallo F; Celis E; Cerundolo V; Clayton A; Colombo MP; Coussens L; Dhodapkar MV; Eggermont AM; Fearon DT; Fridman WH; Fučíková J; Gabrilovich DI; Galon J; Garg A; Ghiringhelli F; Giaccone G; Gilboa E; Gnjatic S; Hoos A; Hosmalin A; Jäger D; Kalinski P; Kärre K; Kepp O; Kiessling R; Kirkwood JM; Klein E; Knuth A; Lewis CE; Liblau R; Lotze MT; Lugli E; Mach J-P; Mattei F; Mavilio D; Melero I; Melief CJ; Mittendorf EA; Moretta L; Odunsi A; Okada H; Palucka AK; Peter ME; Pienta KJ; Porgador A; Prendergast GC; Rabinovich GA; Restifo NP; Rizvi N; Sautès-Fridman C; Schreiber H; Seliger B; Shiku H; Silva-Santos B; Smyth MJ; Speiser DE; Spisek R; Srivastava PK; Talmadge JE; Tartour E; Van Der Burg SH; Van Den Eynde BJ; Vile R; Wagner H; Weber JS; Whiteside TL; Wolchok JD; Zitvogel L; Zou W; Kroemer G
Review: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2014;63(9):977-983

Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy.

Pico de Coaña Y; Masucci G; Hansson J; Kiessling R
Review: JOURNAL OF INTERNAL MEDICINE. 2014;276(2):154-170

Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells.

Mao Y; Poschke I; Kiessling R
Editorial comment: CLINICAL CANCER RESEARCH. 2014;20(6):1401-1403

Myeloid suppressors decrease melanoma survival by abating tumor-fighting T cells.

Kiessling R; Mao Y; Pico de Coaña Y
Review: TRENDS IN MOLECULAR MEDICINE. 2013;19(11):677-684

The two sides of HER2/neu: immune escape versus surveillance.

Seliger B; Kiessling R
Review: JOURNAL OF TRANSLATIONAL MEDICINE. 2013;11:247

HLA-dependent tumour development: a role for tumour associate macrophages?

Marchesi M; Andersson E; Villabona L; Seliger B; Lundqvist A; Kiessling R; Masucci GV
Editorial comment: ONCOIMMUNOLOGY. 2013;2(8):e25157

Cyclooxygenase-2 Steering force of myeloid-derived suppressor cells in cancer?

Mao Y; Poschke I; Kiessling R
Review: CELL DEATH & DISEASE. 2013;4(6):e688

Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation.

Kono K; Mimura K; Kiessling R
Editorial comment: ONCOIMMUNOLOGY. 2012;1(7):1200-1201

Opposing consequences of signaling through EGF family members: Escape from CTLs could be a bait for NK cells.

Kiessling R; Okita R; Mougiakakos D; Mao Y; Sarhan D; Wennerberg E; Seliger B; Lundqvist A; Mimura K; Kono K
Review: CLINICAL IMMUNOLOGY. 2012;144(3):250-268

On the armament and appearances of human myeloid-derived suppressor cells.

Poschke I; Kiessling R
Editorial comment: JOURNAL OF TRANSLATIONAL MEDICINE. 2012;10:104

Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours.

Masucci GV; Wersäll P; Kiessling R; Lundqvist A; Lewensohn R
Other: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2012;61(4):587-591

First International Meeting of the Thematic Centre for Immune Modulatory Therapies for Autoimmunity and Cancer (IMTAC) 13-14 June 2011, Ljusterö, Sweden.

Choudhury A; Höglund P; Kiessling R; Kärre K; Lundqvist A; Malmberg K; Mellstedt H; Scheynius A; Winqvist O; Osterborg A
Review: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2011;60(8):1161-1171

Camouflage and sabotage: tumor escape from the immune system.

Poschke I; Mougiakakos D; Kiessling R
Review: MECHANISMS AND THERAPY OF LIVER CANCER. 2011;111:1-37

Is survivin the potential Achilles' heel of cancer?

Lladser A; Sanhueza C; Kiessling R; Quest AFG
Editorial comment: JOURNAL OF MOLECULAR MEDICINE-JMM. 2010;88(11):1081-1084

Designer lymphocytes to fight cancer: a helping hand from modern molecular biology.

Kiessling R
Review: MECHANISMS AND THERAPY OF LIVER CANCER. 2010;107:57-117

Regulatory T cells in cancer.

Mougiakakos D; Choudhury A; Lladser A; Kiessling R; Johansson CC
Letter: BLOOD. 2009;114(2):488-489

Resistance of naturally occurring regulatory T cells toward oxidative stress: possible link with intracellular catecholamine content and implications for cancer therapy Response

Mougiakakos D; Johansson CC; Kiessling R
Review: MECHANISMS AND THERAPY OF LIVER CANCER. 2009;102:197-227

Oxidative stress and lymphocyte persistence: implications in immunotherapy.

Mehrotra S; Mougiakakos D; Johansson CC; Voelkel-Johnson C; Kiessling R
Editorial comment: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2008;57(4):593-599

Progress in vaccination against cancer-7: report of the meeting in Stockholm, September 10-11, 2007.

Kiessling R; De Geer A; Johansson C; Poschke I; Triulzi C; Vertuani S
Editorial comment: BRITISH JOURNAL OF SURGERY. 2007;94(12):1449-1450

Cancer vaccines.

Kiessling R; Choudhury A
Other: JOURNAL OF IMMUNOLOGY. 2005;174(11):6566-6569

Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. 1986.

Kärre K; Ljunggren HG; Piontek G; Kiessling R
Review: BREAST DISEASE. 2004;20:25-31

Her-2/neu as a paradigm of a tumor-specific target for therapy.

Choudhury A; Kiessling R
Editorial comment: GENE THERAPY. 2004;11(21):1549-1550

HER-2/neu immunotherapies - Take two - get more: optimization strategies for HER-2/neu-based immunotherapies inhibiting carcinogenesis

Seliger B; Kiessling R
Editorial comment: TRENDS IN IMMUNOLOGY. 2002;23(3):130-135

Heat-shock proteins as activators of the innate immune system.

Wallin RPA; Lundqvist A; Moré SH; von Bonin A; Kiessling R; Ljunggren H-G
Review: MECHANISMS AND THERAPY OF LIVER CANCER. 2002;85:101-144

Cellular immunity to the Her-2/neu protooncogene.

Kiessling R; Wei WZ; Herrmann F; Lindencrona JA; Choudhury A; Kono K; Seliger B
Other: TRENDS IN MOLECULAR MEDICINE. 2000;6(9):344-346

Have tumor cells learnt from microorganisms how to fool the immune system? Escape from immune surveillance of tumors and microorganisms: emerging mechanisms and shared strategies.

Kiessling R; Pawelec G; Welsh RM; Barry JD; Ferrone S
Review: CRITICAL REVIEWS IN ONCOGENESIS. 2000;11(2):97-133

Escape mechanisms in tumor immunity: a year 2000 update.

Pawelec G; Heinzel S; Kiessling R; Müller L; Ouyang Q; Zeuthen J
Review: CRITICAL REVIEWS IN ONCOGENESIS. 1999;10(1-2):83-127

Cells and cytokines in immunotherapy and gene therapy of cancer.

Pawelec G; Rees RC; Kiessling R; Madrigal A; Dodi A; Baxevanis C; Gambacorti-Passerini C; Masucci G; Zeuthen J
Published conference paper: RESEARCH IN IMMUNOLOGY. 1998;149(9):877-879

Protective T-cell responses against tumours.

Melief C; Annels N; Dunbar R; Forni G; Kiessling R; Ricciardi-Castagnoli P; Rickinson A; van den Eynde B
Review: LAKARTIDNINGEN. 1997;94(17):1595-1600

[A scientist's day-dream or future reality? Specific immunotherapy against cancer].

Kiessling R; Kärre K
Editorial comment: GUT. 1997;40(1):153-154

Signals from lymphocytes in colon cancer.

Kiessling R
Review: CRITICAL REVIEWS IN ONCOGENESIS. 1997;8(2-3):111-142

Escape from host-antitumor immunity.

Pawelec G; Zeuthen J; Kiessling R
Published conference paper: ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. 1995;756:406-409

Human gamma delta T-cells in the epithelium of the gut and in the inflamed synovial tissue preferentially express the V gamma 8 T-cell receptor chain.

Söderström K; Bucht A; Halapi E; Lundqvist C; Grönberg A; Nilsson E; Orsini DL; van de Wal Y; Koning F; Hammarström ML
Published conference paper: ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. 1995;756:395-399

Phenotype and cytokine profile of intraepithelial lymphocytes in human small and large intestine.

Lundqvist C; Baranov V; Söderström K; Athlin L; Kiessling R; Hammarström S; Hammarström ML
Visa fler

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI